Brokerages Set Biogen Inc. (NASDAQ:BIIB) PT at $184.88

Biogen Inc. (NASDAQ:BIIB) has earned a consensus rating of “Hold” from the twenty-six analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and ten have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $187.8077.

Several equities analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Biogen in a research report on Tuesday. They issued a “neutral” rating and a $185.00 price target on the stock. Guggenheim raised their target price on Biogen from $165.00 to $185.00 in a report on Friday, October 31st. William Blair reaffirmed an “outperform” rating on shares of Biogen in a research report on Wednesday, September 24th. Stifel Nicolaus raised Biogen from a “hold” rating to a “buy” rating and increased their price target for the company from $144.00 to $202.00 in a research report on Thursday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Biogen in a research note on Wednesday, September 24th.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC lifted its position in shares of Biogen by 3.9% during the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after buying an additional 68 shares in the last quarter. CVA Family Office LLC increased its position in shares of Biogen by 18.1% during the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 71 shares during the last quarter. Davis Investment Partners LLC increased its position in shares of Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in Biogen by 22.5% during the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 76 shares during the period. Finally, Wedmont Private Capital boosted its position in Biogen by 3.8% in the second quarter. Wedmont Private Capital now owns 2,190 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 81 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Stock Performance

NASDAQ BIIB opened at $187.62 on Thursday. The company has a market cap of $27.52 billion, a P/E ratio of 17.10, a PEG ratio of 1.56 and a beta of 0.13. The company has a fifty day simple moving average of $173.04 and a 200 day simple moving average of $150.40. The company has a current ratio of 2.72, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. Biogen has a 12-month low of $110.04 and a 12-month high of $190.20.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. The firm had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period last year, the firm earned $4.08 earnings per share. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Sell-side analysts predict that Biogen will post 15.83 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.